LSTA

Lisata TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$5.25

+50.9% vs current

Most likely

Base case

45%

Probability

Target price

$3.40

-2.3% vs current

B-

Bear case

30%

Probability

Target price

$1.20

-65.5% vs current

AI sentiment snapshot

Latest data as of 2026-04-18

AI commentary

Neutral-to-cautious. The deterministic prior is neutral with modest evidence quality and low catalyst density, and the primary-source set points to a monitoring-style special situation: upside is obvious if the merger funds and closes, but current filings show the tender has not started and standalone runway remains tight.

RankAlpha Sentiment Codex - 2026-04-18

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystKuva financing and tender-launch clarityHigh impact

The April 15, 2026 8-K says the purchaser had not yet commenced the tender offer, was seeking alternative financing, and that there was no assurance the offer would commence at all, making near-term financing resolution the key spread driver rather than trial news [#8-K-2026-04-15].

2026-08-31eventMerger closing on revised economicsHigh impact

The March 6, 2026 merger agreement provides for $5.00 per share in cash plus one CVR tied to an NDA or similar filing for certepetide, a meaningfully better headline value than the January term sheet, but realization depends on tender launch and closing conditions being satisfied [#8-K-2026-04-15].

2026-12-31catalystStandalone certepetide data and partnering path if deal slipsHigh impact

If the company remains standalone, the 10-K says final ASCEND study reporting is anticipated in 2026 and notes additional investigator-initiated trial readouts are controlled by academic sponsors, while the same filing also highlights the Catalent ADC licensing path and the return of Greater China rights from Qilu [#10-K-2026-03-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-18 • Updated nightlySource: Internal modelMethodology